Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07284979 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
A Phase 3 study of Obesity, sponsored by Kailera.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,200
- Enrollment target
- 20
- Study locations
NCT07284979 is a Phase 3 study of Obesity that is actively recruiting participants, run by Kailera. The registered enrollment target is 1,200 participants, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (47% higher). The trial reports 20 study locations across 17 states.
The verdict
NCT07284979, a Phase 3 study of Obesity, is actively recruiting participants, sponsored by Kailera.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG KAI-9531
- DRUG Semaglutide
Study Locations (20)
Arizona
- Kailera Clinical Site - Glendale
- Kailera Clinical Site - Phoenix
California
- Kailera Clinical Site - Northridge
- Kailera Clinical Site - Oceanside
Connecticut
- Kailera Clinical Site - Hamden
- Kailera Clinical Site - Stamford
Arkansas
- Kailera Clinical Site - Little Rock
Florida
- Kailera Clinical Site - Orange City
Georgia
- Kailera Clinical Site - Albany
Illinois
- Kailera Clinical Site - Chicago
Kansas
- Kailera Clinical Site - Newton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2025-12-30 |
| Est. Completion | 2028-04-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07284979
The ClinicalTrials.gov registry entry for NCT07284979 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (47% higher). The listed sponsor is Kailera, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07284979 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Arizona, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT07284979 about?
NCT07284979 is a clinical study titled "Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes". The primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.
What is the current status of trial NCT07284979?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,200 participants. The study started on 2025-12-30. Estimated completion is 2028-04-17.
What conditions does trial NCT07284979 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT07284979?
The interventions under investigation include: Placebo (DRUG), KAI-9531 (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT07284979?
This trial is sponsored by Kailera, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07284979 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
-
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.